newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious adverse events in